Robotics
A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patient acquisition to lower-cost recurring referrals — but it must prove the operating-leverage turn at ~$45M revenue before the Avenue debt covenants and a sub-$1.50 stock force another dilutive raise; bullish on the model, watching the proof.
Research
The verdict
A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patient acquisition to lower-cost recurring referrals — but it must prove the operating-leverage turn at ~$45M revenue before the Avenue debt covenants and a sub-$1.50 stock force another dilutive raise; bullish on the model, watching the proof.
Myomo is a wearable medical-robotics company that designs, builds and bills for the MyoPro — a myoelectric-controlled upper-limb orthosis (a rigid powered arm brace) for people with upper-extremity paralysis from stroke, brachial plexus injury, traumatic brain injury, spinal cord injury and other neuromuscular disorders. EMG sensors detect the wearer's own (weak) muscle signal and drive a motor to move the elbow/wrist/hand; if the user stops trying to move, the device stops. The tech was originally developed at MIT with Harvard Medical School clinicians; the company was incorporated in Delaware in 2004 and IPO'd June 2017.
It is registered with the FDA as a Class II device and the product line includes the MyoPro 2x (enhanced flagship, launched Apr 2025), MyoPro Motion W (non-powered multi-articulated wrist, code L8701) and Motion G (powered grasp, code L8702), plus a planned pediatric MyoPal and a next-gen MyoPro 3 in development. In Mar 2026 it launched a mobile app to replace the external laptop previously needed to tune the device.
How it actually makes money — four channels (FY2025):
Contract structure & payment terms. Revenue is recognized at a point in time under ASC 606, on delivery, only once collection is "probable" — and for the largest payer (Medicare Part B) the transaction price is the published CMS fee for codes L8701/L8702 (Medicare pays 80%, the supplement pays the other 20%). The 2026 fees were updated to ~$34,970 (Motion W) and ~$68,800 (Motion G), annually inflation-adjusted. This is not recurring/subscription revenue — every dollar is a one-time device sale that must be re-won through a fresh patient pipeline. The "recurring sources" language in management's pivot means recurring referral channels (rehab clinics, O&P) that lower acquisition cost, not recurring billings.
Key operating funnel metrics (the real KPIs):
Map: upstream component & raw-material vendors → Myomo in-house design + 3D-printing + fabrication (Burlington, MA) → patient (direct) / O&P provider / VA / international distributor → payer (CMS, Medicare Advantage, commercial, German statutory insurers).
Named stakeholders along the chain: CMS / Medicare (payer-in-chief), Medicare Advantage plans, German statutory insurers, Veterans Health Administration (130+ facilities), O&P providers in the US, UK, Germany, Denmark, Italy, Australia, Avenue Capital (senior secured lender), and the former Ryzur Medical / Chinaleaf Capital JV partners.
The single strongest fact in this dossier: Myomo is effectively a category-of-one. Per its own competitive disclosure, people with arm/wrist/hand paralysis "have few options to regain function" — the alternatives are (a) rehabilitation therapy (the standard of care and a prerequisite to qualifying for a MyoPro, not a substitute), (b) non-powered braces (which clinicians deliberately screen out as too simple for these patients), (c) exoskeleton suits (Lifeward/ReWalk, Ekso Bionics, Cyberdyne — but these address lower-extremity stand/walk, not the arm), and (d) implantable devices. No named company sells a directly competing myoelectric upper-limb orthosis at scale.
The durable moats:
Bargaining power is asymmetric and unfavorable on the demand side. Myomo has strong power over its small component suppliers, but near-zero power over CMS — a single CMS coverage or fee decision can swing the entire P&L. That payer dependency is the mirror image of the reimbursement moat (Lens 13).
Myomo reports one operating segment, one product family (versions of the MyoPro); the CEO/CODM manages on a consolidated basis. So "segments" = channel + geography, which are disclosed:
By channel (FY2025 vs FY2024):
| Channel | FY2025 | FY2024 | YoY | Read |
|---|---|---|---|---|
| Direct billing | $30.42M | $25.33M | +20% | Core; growth dampened by lead-gen/acquisition problems |
| International | $6.76M | $4.55M | +48% | Fastest, Germany-led; record |
| U.S. O&P | $2.92M | $1.46M | +100% | Small but doubling — the pivot channel |
| VA | $0.83M | $1.20M | −31% | Lumpy, declining |
| Total | $40.93M | $32.55M | +26% |
By geography: FY2025 ran ~83% US / ~17% international; Q1 2026 was 80% US / 20% Germany vs 87%/13% in Q1 2025 — international mix is rising.
The trend that matters (decelerating + mix-shifting): full-year FY2025 grew +26%, but Q1 2026 grew only +3% YoY ($10.11M vs $9.83M). The cause is deliberate: management is throttling the high-cost direct-to-patient advertising that drove 2025 and leaning on cheaper referral channels, so near-term direct-billing growth slows while International (+53% in Q1) and U.S. O&P (+79% in Q1) accelerate off small bases. Recurring referral sources hit 49% of Q1 2026 revenue, up from 25% a year earlier — the single best evidence the channel mix is genuinely re-architecting.
Unusual vs its own history: revenue growth collapsed from +26% (FY2025) to +3% (Q1) — a self-inflicted air-pocket from cutting advertising before the referral engine fully replaces it. Whether Q2–Q4 re-accelerate to hit the $43–46M guide is the 2026 question.
No transcripts on disk (transcripts/ empty); this lens is ``.
Management tone on the Q1 2026 call was "steady gains amid headwinds". The recurring throughline across recent communication is the go-to-market pivot: from ad-funded direct-to-patient toward MyoConnect (referral program) + O&P. New specifics disclosed on the Q1 call: MyoConnect scaled to 150+ referring rehab facilities in nine months, delivering pre-qualified leads with better medical-conversion potential; the company added a new marketing executive and a new digital-ad agency in Q1 and refined data-driven targeting; patient-acquisition cost ("Cost per Pipeline Add") is being driven down while pipeline adds per lead rise.
Phrases emphasized now: "recurring sources," "Cost per Pipeline Add," "operating leverage," "MyoConnect," "O&P channel," "Germany/international record." Phrases receding: the 2024–25 emphasis on scaling direct-to-patient TV/social advertising — management is explicitly de-emphasizing the channel that built 2025's revenue. The sentiment shift is from "spend to grow the funnel" → "grow the funnel cheaper and convert faster." Credible, but unproven at the revenue line until H2 2026.
The index files Myomo under "robotics," but its true peer set is pure-play wearable medical-robotics / exoskeleton micro-caps, not humanoid or lidar names. All three are unprofitable; P/E is n/a. Multiples are ``.
| Company | Ticker | Mkt cap | EV | P/S | EV/Sales | TTM rev | Gross margin | TTM rev growth |
|---|---|---|---|---|---|---|---|---|
| Myomo | MYO | $49.5M | $52.7M | 1.20× | 1.28× | $41.2M | 66.0% | +26% (FY25) |
| Ekso Bionics | EKSO | $42.0M | n/a | 3.34× | n/a | $12.8M | n/a | −28.6% (FY25) |
| Lifeward (ex-ReWalk) | LFWD | $19.5M | $16.8M | 0.93× | 0.80× | $20.9M | 36.6% | n/a |
| 5-yr avg ROE (all three) | — | — | — | — | — | — | — | n/a — negative equity returns; not meaningful |
Larger-cap "robotics/medtech" reference points for scale only (not direct comps): Intuitive Surgical (ISRG) and PROCEPT BioRobotics (PRCT) trade at premium growth-medtech multiples an order of magnitude above these micro-caps — n/a — specific multiples not sourced this run.
The read: Myomo is the biggest, fastest-growing and highest-gross-margin of the three pure-plays, yet trades at 1.2× sales — below shrinking Ekso at 3.3× and only modestly above declining-margin Lifeward. The market is pricing MYO as a structurally-impaired micro-cap, not as the reimbursement-moat compounder its unit economics suggest. That gap is the entire bull case (Lens 12) — and the dividend yield is 0% across the group.
Mostly ``, corroborated by filing milestones.
What the tape reveals: this name reacts to exactly two things — (1) CMS reimbursement decisions (the franchise) and (2) capital structure events (dilutive raises, debt, going-concern fear). Quarterly revenue beats/misses move it far less than either. That is the dossier's most important behavioral fact for sizing a position.
Capital-allocation history — mixed-to-poor by necessity. The company has never been profitable (accumulated deficit −$121.7M at Q1 2026) and has funded itself through serial dilution + debt. ROE/ROIC are negative and not meaningful. The judgment call: was the 67% FY2025 surge in selling/marketing (to $20.4M) that produced only +26% revenue a disciplined growth investment or value destruction? Adjusted EBITDA more than doubling its loss to −$11.46M (FY2025) vs −$5.13M (FY2024) argues the latter — and management has now effectively admitted it by pivoting away from that spend. The 2026 plan (opex growth ≤ ½ revenue growth) is the corrective.
Skin in the game: insider-transactions.csv not present; insider ownership not sourced this run — n/a.
Red flags: no related-party self-dealing surfaced; the main governance watch-item is dilution (pre-funded warrants, the Avenue conversion feature, the 4%/yr evergreen option-plan top-up) rather than misconduct.
Acting as a forensic analyst; every figure labeled.
Regulatory findings (required).
regulatory/regulatory-findings.md reports 0 SEC Litigation Releases and 0 AAERs naming Myomo over 2021-06-20→2026-06-20 (EDGAR EFTS LR + AAER search).Bottom-up from the latest actuals + guidance. No forecast.ts create logged — this is the --watchlist breadth loop (per skill, skip the Brier log). Output ``, inputs labeled.
Anchors: FY2025 revenue $40.93M, GM 65.7%, GAAP net loss −$15.57M, Adj EBITDA −$11.46M. FY2026 guide $43–46M revenue with opex growth ≤ ½ revenue growth. Company is loss-making → the meaningful projection is revenue + path-to-breakeven, not EPS; EPS stays negative across the window.
| Scenario | FY2026 rev | FY2027 rev | FY2028 rev | Logic |
|---|---|---|---|---|
| Bull | $46M (top of guide) | ~$56M | ~$68M | Referral engine + International + O&P compound ~22%/yr; opex leverage drives Adj-EBITDA breakeven in late FY2027 |
| Base | $44.5M (mid-guide, +9%) | ~$51M (+15%) | ~$58M (+14%) | Pivot works but direct-billing stays soft; Adj-EBITDA breakeven slips to FY2028 |
| Bear | $42M (low of guide, +3%) | ~$44M (+5%) | ~$45M (+2%) | Ad-cut air-pocket isn't replaced fast enough; growth stalls, a dilutive raise resets the model |
EPS: remains negative in all three through FY2028 — there is no fiscal year in this window where a positive non-GAAP EPS line is defensible from the current cost base; modeling one would be a fabrication. The honest forward metric is "does Adjusted EBITDA cross zero, and is it self-funded when it does?" Base case: breakeven ~FY2028, requiring at least one more capital event (the undrawn $5M Avenue tranche and/or equity) to bridge there given ~$10–12M annual burn against $15.7M liquidity.
The number that decides it: hitting the $43–46M FY2026 guide while holding opex growth to ≤½ of revenue growth would cut the Adj-EBITDA loss toward ~−$6–8M and validate the leverage turn. Missing the low end risks tripping the 75%-of-projected-revenue covenant — a binary downside.
Bull case. Myomo owns a regulatory monopoly on a reimbursed, clinically-validated solution for a condition with no real alternative — a 6.3M-stroke US prevalence pool, 400–500k new strokes/yr, of which the company believes 40,000–80,000 new patients/yr are MyoPro-suitable. Against that TAM it did just ~700–800 revenue units. The CMS lump-sum reimbursement (codes locked, ASP rising +9% on inflation) is the moat; the 2026 pivot finally aligns the cost structure with the model — recurring referrals already 49% of revenue (up from 25%), International +53%, O&P +79%, gross margin 66–68%. If opex discipline holds, this is a high-gross-margin medical-device compounder trading at 1.2× sales — cheaper than a shrinking Ekso at 3.3×. Three analysts rate it Strong Buy with targets of $4.32–$7.67.
Bear case (permanent-impairment risks). (1) CMS dependency — one adverse coverage/fee decision on L8701/L8702 vaporizes ~half the revenue overnight; this is concentration risk dressed as a moat. (2) Capital-structure fragility — never profitable, −$121.7M accumulated deficit, ~$11M/yr burn, only $15.7M liquidity, and covenant-laden 26%-yield secured debt that turns a revenue miss into a liquidity event; the realistic path requires further dilution from a sub-$1.50 stock (maximally dilutive). (3) Growth durability — backlog −27% and Q1 revenue +3% show the ad-funded engine was buying growth that doesn't recur, and the referral replacement is unproven at the revenue line.
Pre-mortem (18 months out, thesis broke): Q2–Q3 2026 revenue undershot the $43–46M guide because MyoConnect referrals converted slower than direct-billing leads; the 75%-of-projected-revenue covenant tightened; Myomo drew the $5M tranche and did an emergency equity raise at ~$1, the share count ballooned, and a second reverse split (echoing Jan 2020) was needed to hold the NYSE American $1 listing minimum. The product was never the problem — the funding bridge was.
Are multiples too high? No — at 1.2× sales / 1.28× EV-Sales with 66% gross margin and +26% FY2025 growth, MYO is arguably cheap on fundamentals. The discount is the market pricing the financing/dilution risk, not the business.
Contrarian view (what the market refuses to see): the market treats MYO as a perpetually-dilutive zombie, but it is one or two clean quarters of operating leverage away from re-rating — the reimbursement moat is real and the cost pivot is already showing in the mix. The market is anchored on the −82% chart and the cap table, not on the unit economics.
Dismantling the bull case.
The only profitable humanoid maker and #1 by volume — but the float is a Shanghai-only embodied-AI bet whose revenue is 74% lab demos, not labor replacement, and whose Western TAM is being legislated to zero.
A profitable EV maker priced as a solved-autonomy robotics company — the car business is shrinking, the GAAP profit prop (reg credits) is going to zero, and the entire ~190x multiple now rents on robotaxi + Optimus execution that is real but years behind the price.
A genuinely differentiated case-handling robotics moat wrapped around an ungovernable accounting-and-concentration core — adverse ICFR opinion + active SEC whistleblower probe + >90% Walmart revenue means the multiple is pricing a clean compounder that the filings say does not yet exist.